3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
21
Triple Negative Breast Neoplasms
12
Inflammatory Breast Neoplasms
2
Carcinoma, Adenoid Cystic
2
Resectable HER2-positive Breast Cancer
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplastic Cells, Circulating
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Hodgkin Disease
1
HR+/HER2- Breast Cancer
1
Epstein-Barr Virus Infections
1
Down Syndrome
1
CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
1
Interventions
Gemcitabine
32
Cisplatin
31
durvalumab
15
pembrolizumab
14
Fluorouracil
13
Oxaliplatin
12
Leucovorin
12
Capecitabine
10
Bevacizumab
8
lenvatinib
7
Nivolumab
7
zanidatamab
4
Trastuzumab
4
S 1 (combination)
4
Paclitaxel
4
Liquid Biopsy
4
Irinotecan
4
Carboplatin
4
Albumin-Bound Paclitaxel
4
tremelimumab
3
tislelizumab
3
irinotecan sucrosofate
3
Injections
3
Folfox protocol
3
130-nm albumin-bound paclitaxel
3
toripalimab
2
pertuzumab
2
niraparib
2
ivosidenib
2
envafolimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
Epirubicin
×
1 year
×
Clear all
No trials found.